文献速递炎症性肠病

基线药物清除率预测接受维得利珠单抗治疗的炎症性肠病患儿结局:VedoKids 前瞻性多中心研究结果

Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study.
PubMed 文献 · Aliment Pharmacol Ther · 2025-01-15

VedoKids 前瞻性多中心研究纳入 129 例炎症性肠病患儿,基于 312 份血清维得利珠单抗浓度建立群体药代动力学模型,评估暴露-反应关系。第 30 周时 39 例(31%)达到深度生化缓解;基线药物清除率升高与 ESR/CRP 定义的深度生化缓解率降低相关(OR 0.47,95%CI 0.2-1.05,p=0.08),与钙卫蛋白<100 μg/g 定义的缓解率降低相关(OR 0.13,95%CI 0.1-0.79,p<0.05)。

要点

  • 基线药物清除率升高与第 30 周深度生化缓解率降低相关。
  • 体重较高和血清白蛋白较低与药物清除率增加相关(p<0.001)。
  • 模拟模型显示体重≤30 kg 患儿采用分层固定给药方案与成人药物浓度最匹配。

核心结论

  • 药物清除率受血清白蛋白强烈影响;基线清除率可预测第 30 周深度生化缓解。
  • 需要进一步研究以更好地理解最佳给药策略,尤其是接受维得利珠单抗的低体重患儿。

研究设计与样本

  • VedoKids 前瞻性多中心研究,纳入 129 例炎症性肠病患儿,基于 312 份血清维得利珠单抗浓度,以已发表的成人模型作为贝叶斯先验建立药代动力学模型。

主要发现

  • 第 30 周时 104/129(81%)患儿仍在接受维得利珠单抗治疗(53% 女性,47% 克罗恩病)。
  • 暴露-反应评估中 39 例(31%)达到深度生化缓解。
  • 基线药物清除率升高与第 30 周基于 ESR/CRP 的深度生化缓解率降低相关(OR 0.47,95%CI 0.2-1.05,p=0.08)。
  • 基线药物清除率升高与第 30 周钙卫蛋白<100 μg/g 的深度生化缓解率降低相关(OR 0.13,95%CI 0.1-0.79,p<0.05)。
  • 体重较高和血清白蛋白较低与药物清除率增加相关(p<0.001)。

关键数值与推荐

  • 深度生化缓解定义为 CRP/ESR 正常且无激素缓解。
  • 模拟模型发现,对于体重≤30 kg 的患儿,分层固定给药方案与成人药物浓度最匹配。

局限性

  • 需要进一步研究以更好地理解最佳给药策略,尤其是接受维得利珠单抗的低体重患儿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pharmacokinetics of biologic agents can differ between children and adults with inflammatory bowel disease (IBD), often necessitating modified paediatric dosing strategies. AIMS: To define the exposure-response relationship of vedolizumab in the paediatric IBD VedoKids cohort including the effect of baseline clearance on deep biochemical remission (normal C-reactive protein [CRP]/erythrocyte sedimentation rate [ESR] and steroid-free remission) at 30 weeks, and to use population pharmacokinetic models to find the best matches between adult and paediatric pharmacokinetic profiles. METHODS: We sought a pharmacokinetic model on 312 serum vedolizumab concentrations from 129 children, assisted by a published adult model as a Bayesian prior. We employed the model for exposure-response evaluation and for investigating doses in paediatric patients to match the adult exposure at the labelled dose. RESULTS: At Week 30, 104/129 (81%) children (53% female and 47% Crohn disease) remained on vedolizumab, of whom 39 (31%) in the exposure-response evaluation were in deep biochemical remission. Increased baseline drug clearance was associated with lower deep biochemical remission rates at Week 30 based on ESR/CRP (OR 0.47 [95% CI 0.2-1.05, p = 0.08]) and calprotectin < 100 μg/g (OR 0.13 [95% CI 0.1-0.79, p < 0.05]). Higher weight and lower serum albumin were associated with increased clearance (p < 0.001). Simulation models found that, for children ≤ 30 kg, tiered fixed dosing regimens best matched adult drug concentrations. CONCLUSIONS: Drug clearance was strongly influenced by serum albumin. Baseline clearance predicted deep biochemical remission at Week 30. Further investigation is needed to better understand optimal dosing strategies-especially for lower-weight children receiving vedolizumab.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Stein R, Turner D, Hussey S, et al. Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study. Aliment Pharmacol Ther. 2025. PMID: 39812549. doi:10.1111/apt.18484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。